MUC16 and cancer: The AUC for benign versus malignant tumours in patients managed with and without surgery combined was reported in two studies (5167 tumours, 18 centres, and eight countries) with a summary estimate of 0.94 (95% confidence interval 0.93 to 0.96, 95% prediction interval 0.88 to 0.99) for ADNEX with CA125 (table 2).6 7 ADNEX without CA125 was assessed in only one study (4905 tumours, 17 centres, and seven countries).6 This study reported a summary AUC of 0.94 (95% confidence interval 0.91 to 0.95, 95% prediction interval 0.82 to 0.98).